Urgent Studies Needed On Paxlovid! Does It Only Help Alleviate Symptoms And Suppress Viral Load For A While But Does Not Help In Total Viral Clearance?
We at Thailand Medical News
think that urgent studies are needed by independent and credible researchers with regards to Pfizer’s Paxlovid as there are many now many unpublished case reports by both physicians and also patients reporting anomalies when the so-called antiviral drug is used to treat COVID-19 patients.
One common occurrence being reported is that many when tested positive for SARS-CoV-2 and were symptomatic, upon treatment with Paxlovid for about five days, had their symptoms reduced or totally gone and typically tested negative, but then a few days later would again test positive and again have symptoms manifesting again.
In a few cases, their conditions actually deteriorated and required hospitalizations, according to physicians in the United States, United Kingdom and even China.
Two health centers in the United States ie one in California and another in Massachusetts (both have requested anonymity for now) reported that they found that patients who tested positive for SARS-CoV-2, initially had lower viral loads after being treated with Paxlovid but these viral loads reverted back to higher values in days 6 to 8 after initial start of treatment.
Interestingly, one patient from the California despite having tested negative via nasal PCR test and had symptom resolution upon discharged, displayed viral persistence 58 days later via serological tests.
Considering the number of such cases coming up as being reported by various physicians unofficially, a detailed study is warranted urgently.
There could be many factors at play ie Paxlovid might not be an effective antiviral after all and it could leave room for viral persistence issues or the new emerging SARS-CoV-2 variants could be developing drug resistance to Paxlovid.
Either way, a proper study by independent researchers would help clear up the air about these anomalies.
Thailand Medical News
will keep on providing more updates on Paxlovid usage.